EC
PRLD icon

EcoR1 Capital’s Prelude Therapeutics PRLD Stock Holding History

EcoR1 Capital’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-947,049
Closed -$3.24M – 39
2026
Q1 		$3.24M Buy
+947,049
New +$2.48M 0.14% 26
2023
Q4 		– Sell
-1,157,452
Closed -$3.58M – 54
2023
Q3 		$3.58M Hold
1,157,452
– – 0.12% 41
2023
Q2 		$5.21M Buy
+1,157,452
New +$6.92M 0.13% 40

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

EcoR1 Capital's PRLD Position: Q2 2026 in Review

EcoR1 Capital sold out of Prelude Therapeutics (PRLD) in Q2 2026, closing a stake of 947,049 shares — an estimated $3.24M sold.

EcoR1 Capital first reported a position in PRLD in Q2 2023 and held it in 3 quarters. The position peaked at $5.21M in Q2 2023. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • EcoR1 Capital reported no remaining Prelude Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EcoR1 Capital sold 947,049 Prelude Therapeutics shares in Q2 2026, an estimated $3.24M.
  • EcoR1 Capital first reported a position in Prelude Therapeutics in Q2 2023 and held it in 3 quarters.
  • EcoR1 Capital's Prelude Therapeutics position peaked at $5.21M in Q2 2023.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.